Vote Yes on this bill if you want to extend federal ALS research and treatment-access programs through 2031, strengthen safety oversight in trials, and require the FDA to plan and report on progress for rare neurodegenerative diseases.

Organizations that support this bill may include ALS patient advocacy groups, medical research organizations, neurologists, hospitals, and rare disease nonprofits that want continued federal help to speed treatment development.

Vote No on this bill if you want to let the current ALS program expire sooner, avoid continuing federal spending in this area, or limit new trial reporting rules and FDA planning requirements.

Organizations that oppose this bill may include budget watchdog groups, limited-government advocates, or drug industry groups concerned about extending federal programs and adding reporting requirements to clinical trials.